Brasada Capital Management LP increased its holdings in Zoetis Inc (NYSE:ZTS) by 6.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,204 shares of the company’s stock after acquiring an additional 4,658 shares during the period. Zoetis comprises about 2.6% of Brasada Capital Management LP’s holdings, making the stock its 9th largest holding. Brasada Capital Management LP’s holdings in Zoetis were worth $9,868,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Commerce Bank lifted its stake in Zoetis by 1.5% in the 2nd quarter. Commerce Bank now owns 81,495 shares of the company’s stock worth $9,249,000 after acquiring an additional 1,198 shares in the last quarter. Barrett Asset Management LLC increased its position in Zoetis by 385.6% in the 2nd quarter. Barrett Asset Management LLC now owns 189,195 shares of the company’s stock worth $21,472,000 after purchasing an additional 150,235 shares during the last quarter. Echo Street Capital Management LLC increased its position in Zoetis by 46.1% in the 2nd quarter. Echo Street Capital Management LLC now owns 289,327 shares of the company’s stock worth $32,836,000 after purchasing an additional 91,304 shares during the last quarter. Callahan Advisors LLC increased its position in Zoetis by 80.0% in the 3rd quarter. Callahan Advisors LLC now owns 11,610 shares of the company’s stock worth $1,447,000 after purchasing an additional 5,160 shares during the last quarter. Finally, Greenleaf Trust increased its position in Zoetis by 9.0% in the 2nd quarter. Greenleaf Trust now owns 3,811 shares of the company’s stock worth $433,000 after purchasing an additional 315 shares during the last quarter. 89.95% of the stock is owned by hedge funds and other institutional investors.
In related news, EVP Kristin C. Peck sold 11,500 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $123.22, for a total transaction of $1,417,030.00. Following the completion of the sale, the executive vice president now owns 48,877 shares in the company, valued at approximately $6,022,623.94. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Roxanne Lagano sold 4,463 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $125.99, for a total value of $562,293.37. Following the sale, the executive vice president now owns 33,190 shares of the company’s stock, valued at approximately $4,181,608.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,332 shares of company stock valued at $4,258,182. 0.29% of the stock is owned by corporate insiders.
Several research analysts have weighed in on ZTS shares. Morgan Stanley increased their price objective on Zoetis from $100.00 to $136.00 and gave the company an “equal weight” rating in a report on Monday, September 30th. SunTrust Banks increased their price objective on Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a report on Tuesday, August 13th. ValuEngine lowered Zoetis from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Argus set a $140.00 price objective on Zoetis and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, Credit Suisse Group set a $138.00 price objective on Zoetis and gave the company a “buy” rating in a report on Friday, October 11th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Zoetis currently has an average rating of “Buy” and an average price target of $125.20.
Shares of NYSE ZTS opened at $117.86 on Friday. The company has a debt-to-equity ratio of 2.74, a quick ratio of 2.87 and a current ratio of 4.17. The firm has a market cap of $57.43 billion, a price-to-earnings ratio of 37.65, a P/E/G ratio of 2.98 and a beta of 0.88. The business’s 50-day simple moving average is $125.46 and its 200-day simple moving average is $116.48. Zoetis Inc has a 52 week low of $78.90 and a 52 week high of $130.20.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.94 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.06. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.58 billion. During the same quarter in the prior year, the firm posted $0.83 EPS. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. As a group, equities research analysts forecast that Zoetis Inc will post 3.57 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Tuesday, October 22nd will be paid a dividend of $0.164 per share. The ex-dividend date is Monday, October 21st. This represents a $0.66 annualized dividend and a yield of 0.56%. Zoetis’s payout ratio is 21.09%.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: What is an Initial Public Offering (IPO)?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.